Tag Archives: Strategy

Clayton Christensen on the Future of Pharma

A keynote speaker at the 9thAnnual SaS Health Care & Life Sciences Executive Conference on May 10, ‘disruptive’ author of The Innovator’s Dilemma and Harvard business professor Clayton Christensen sat down with PharmExec to discuss the future of the pharmaceutical industry, and what Mitt Romney could bring to the White House.
Posted in Biotech, Events, FDA, healthcare, IP, leadership, People, R&D, Regulatory, Safety, Technology, Uncategorized | Also tagged , , , , , , , , , , , | 1 Comment

Dare to Compare: Genzyme Bets on MS

Riding positive data on a late-phase multiple sclerosis drug, Genzyme execs talked up the company’s willingness to go head-to-head against Rebif, EMD Serono and Pfizer’s blockbuster beta interferon. Genzyme execs didn’t go so far as to reiterate former CEO Henri Termeer’s 2010 prediction of $3 billion plus in potential sales for Lemtrada (alemtuzumab), but they […]
Posted in Biotech, Events, FDA, Global, IP, R&D, Regulatory, Safety, Sales, Strategy, Technology | Also tagged , , | 1 Comment

Doing More With Less: A Leadership Perspective

Steven Blum, Director of Health Economics at Forest Laboratories and one of Pharm Exec’s 2011 Emerging Pharma leaders, recently spoke with Associate Editor Jennifer Ringler on building leadership and team rapport in today’s lean organization.
Posted in Agency Insight, Corporate Responsibility, leadership | Also tagged , , , , | 2 Comments

Pharma Complexity Is Leading to Loss of Profits

It will take far more than factory closures to simplify the pharma industry, write Melvin Jay and Professor Simon Collinson. When pharmaceutical giant Novartis announced it was likely to close its West Sussex (UK) factory, it came as no surprise to the pharmaceutical industry — as Pfizer, AstraZeneca and Glaxo had done the same. While […]
Posted in Strategy | Also tagged , , | 3 Comments

Former EMA Head Back in the Regulatory Saddle

His decade-long tenure as head of the European Medicines Agency (EMA) may have ended, but Thomas Lönngren is already back in the regulatory saddle as a strategic advisor to NDA Group, an independent consulting group focused on reducing wasted drug development costs, ensuring new medicines get to market faster, and “improving the performance of the […]
Posted in Europe, Global, leadership, Market Access, People, pricing, R&D, Regulatory | Also tagged , , , | Leave a comment
  • Categories

  • Meta